AMAL vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMAL's Piotroski F-Score of 4/9 indicates a weak financial health profile, signaling potential operational inefficiencies or instability despite solid profitability metrics. The absence of an Altman Z-Score raises concern about default risk, especially given the lack of available leverage and liquidity data. While the stock trades below its intrinsic value of $80.65 and Graham Number of $45.21, suggesting undervaluation, the current price of $38.10 is significantly below both benchmarks, implying either deep value or market skepticism. Strong earnings growth (11.1% YoY) and consistent beat rates (3/4 in last 4 quarters) support future potential, but technical trends and insider selling undermine near-term momentum.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
AMAL vs JPM: Head-to-Head Comparison
This page compares Amalgamated Financial Corp. (AMAL) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.